Obesity Interventions – Market Insights – United States

The rise of GLP-1 receptor agonists is significantly transforming the landscape of obesity treatment, impacting the growth of bariatric procedures and affecting device sales. Innovations and future reimbursements in the GLP-1 space are expected to continue placing downward pressure on the demand for bariatric procedures. Despite this, the growing obese population and increased treatment rates are anticipated to drive the obesity intervention market. Additionally, less-invasive endoluminal procedures and the adoption of innovative technologies that command higher prices will contribute to sustaining the obesity intervention market.

This Medtech 360 report provides comprehensive data and analysis on the state of the obesity intervention market in the US from 2019 through 2034.

GLP-1 receptor agonists have been experiencing a meteoric rise in adoption among the US patient population in recent years.

How has the rise in GLP-1 receptor agonist prescriptions affected the obesity intervention market?

Will the obesity intervention market recover from the increasing use of GLP-1 receptor agonists?

Considering the emerging pharmacological therapies in the pipeline, what is the long-term outlook for bariatric surgery procedures?

Can there be a complementary use of GLP-1 receptor agonists and bariatric surgery?

What strategies can competitors within the obesity intervention market employ to adapt to the increasing use of GLP-1 receptor agonists?

Robotic-assisted bariatric procedures will support the overall obesity intervention market.

Which procedure types have the highest and lowest laparoscopic technique penetration amid the growing influence of robotic surgery?

Given the rise of robotic surgery, which laparoscopic bariatric procedures are still growing, and which ones are nearing saturation?

Which technique—open or laparoscopic—is more affected by the rise of robotic surgery?

There is a growing trend among US physicians to adopt novel bariatric procedures for weight loss.

What are these new procedures?

What will be the expected growth rate of these procedures over the forecast period?

New competitors are expected to enter this space within the forecast period.

Who are these competitors and what products are they bringing to the market?

Which segments are seeing the most incoming competitors?